Medacta Financial Statements From 2010 to 2025
| MEDGF Stock | USD 83.91 0.00 0.00% |
Check Medacta Group financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Medacta Group's main balance sheet or income statement drivers, such as , as well as many indicators such as . Medacta financial statements analysis is a perfect complement when working with Medacta Group Valuation or Volatility modules.
Medacta |
Medacta Group SA Company Return On Asset Analysis
Medacta Group's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Medacta Group Return On Asset | 0.0752 |
Most of Medacta Group's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Medacta Group SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Medacta Group SA has a Return On Asset of 0.0752. This is 100.86% lower than that of the Healthcare sector and 100.42% lower than that of the Medical Devices industry. The return on asset for all United States stocks is 153.71% lower than that of the firm.
Medacta Group SA Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Medacta Group's current stock value. Our valuation model uses many indicators to compare Medacta Group value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Medacta Group competition to find correlations between indicators driving Medacta Group's intrinsic value. More Info.Medacta Group SA is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers reporting about 0.35 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Medacta Group SA is roughly 2.84 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Medacta Group's earnings, one of the primary drivers of an investment's value.About Medacta Group Financial Statements
Medacta Group stakeholders use historical fundamental indicators, such as Medacta Group's revenue or net income, to determine how well the company is positioned to perform in the future. Although Medacta Group investors may analyze each financial statement separately, they are all interrelated. For example, changes in Medacta Group's assets and liabilities are reflected in the revenues and expenses on Medacta Group's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Medacta Group SA. Please read more on our technical analysis and fundamental analysis pages.
Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical medical devices Europe, North America, the Asia-Pacific, and internationally. The company was founded in 1958 and is headquartered in Castel San Pietro, Switzerland. Medacta Group operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 1421 people.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Medacta Pink Sheet
Medacta Group financial ratios help investors to determine whether Medacta Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medacta with respect to the benefits of owning Medacta Group security.